BIOLASE (BIOL) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock BIOL vs. BJDX, NAOV, BBLG, DYNT, NUWE, TTOO, IONM, HSDT, SDCCQ, and GMVDFShould you be buying BIOLASE stock or one of its competitors? The main competitors of BIOLASE include Bluejay Diagnostics (BJDX), Nanovibronix (NAOV), Bone Biologics (BBLG), Dynatronics (DYNT), Nuwellis (NUWE), T2 Biosystems (TTOO), Assure (IONM), Helius Medical Technologies (HSDT), SmileDirectClub (SDCCQ), and G Medical Innovations (GMVDF). These companies are all part of the "medical equipment" industry. BIOLASE vs. Its Competitors Bluejay Diagnostics Nanovibronix Bone Biologics Dynatronics Nuwellis T2 Biosystems Assure Helius Medical Technologies SmileDirectClub G Medical Innovations BIOLASE (NASDAQ:BIOL) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends. Which has higher valuation and earnings, BIOL or BJDX? Bluejay Diagnostics has lower revenue, but higher earnings than BIOLASE. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBIOLASE$48.83M0.00-$20.63M-$14.94N/ABluejay Diagnostics$250K7.81-$7.72M-$125.15-0.01 Which has more volatility and risk, BIOL or BJDX? BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Do analysts recommend BIOL or BJDX? BIOLASE currently has a consensus price target of $1.20, indicating a potential upside of 0.00%. Given BIOLASE's stronger consensus rating and higher probable upside, equities analysts plainly believe BIOLASE is more favorable than Bluejay Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Bluejay Diagnostics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is BIOL or BJDX more profitable? Bluejay Diagnostics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bluejay Diagnostics' return on equity of -362.07% beat BIOLASE's return on equity.Company Net Margins Return on Equity Return on Assets BIOLASE-41.65% -1,782.73% -55.31% Bluejay Diagnostics N/A -362.07%-299.10% Do insiders & institutionals have more ownership in BIOL or BJDX? 8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by company insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor BIOL or BJDX? In the previous week, Bluejay Diagnostics had 4 more articles in the media than BIOLASE. MarketBeat recorded 4 mentions for Bluejay Diagnostics and 0 mentions for BIOLASE. Bluejay Diagnostics' average media sentiment score of 0.45 beat BIOLASE's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the news media. Company Overall Sentiment BIOLASE Neutral Bluejay Diagnostics Neutral SummaryBIOLASE beats Bluejay Diagnostics on 9 of the 15 factors compared between the two stocks. Get BIOLASE News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOL vs. The Competition Export to ExcelMetricBIOLASEDental equipment & supplies IndustryMedical SectorNASDAQ ExchangeMarket Cap$581K$9K$5.61B$9.84BDividend YieldN/AN/A4.61%4.07%P/E Ratio0.00N/A30.2925.74Price / SalesN/A0.00463.41115.83Price / CashN/AN/A38.2159.48Price / BookN/A0.008.826.15Net Income-$20.63M-$60.92M$3.25B$265.06M BIOLASE Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOLBIOLASE0.9211 of 5 starsN/A$1.20+∞N/A$581K$48.83M0.00160BJDXBluejay Diagnostics0.646 of 5 stars$1.88+34.3%N/A-91.2%$2.09M$250K-0.029Short Interest ↑Gap UpHigh Trading VolumeNAOVNanovibronix0.2752 of 5 stars$0.77-3.5%N/A-90.1%$2.07M$2.56M-0.0620News CoverageNegative NewsStock SplitGap DownBBLGBone Biologics1.6747 of 5 stars$2.36+1.3%N/A-71.6%$1.27MN/A0.002Earnings ReportShort Interest ↓DYNTDynatronicsN/A$0.09+2.3%N/A-47.1%$1.19M$33.60M-0.11200Gap UpNUWENuwellis1.4167 of 5 stars$4.96-4.6%$714.00+14,295.2%-94.1%$550K$8.74M-0.0170News CoverageEarnings ReportShort Interest ↓TTOOT2 BiosystemsN/A$0.02+5.9%N/A-99.5%$379K$7.68M0.00180Positive NewsShort Interest ↓IONMAssureN/A$0.05flatN/AN/A$150K$149K0.00130HSDTHelius Medical Technologies0.4936 of 5 stars$5.82-1.9%N/A-98.9%$80K$520K0.0030Earnings ReportShort Interest ↑SDCCQSmileDirectClubN/A$0.00-99.0%N/AN/A$40K$470.74M0.002,700Gap DownHigh Trading VolumeGMVDFG Medical InnovationsN/AN/AN/AN/A$26K$4.42M0.0072 Related Companies and Tools Related Companies Bluejay Diagnostics Alternatives Nanovibronix Alternatives Bone Biologics Alternatives Dynatronics Alternatives Nuwellis Alternatives T2 Biosystems Alternatives Assure Alternatives Helius Medical Technologies Alternatives SmileDirectClub Alternatives G Medical Innovations Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOL) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BIOLASE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access